Patients in the highest Atherogenic Index of Plasma quartile had a 7.892-fold increased risk of major adverse cardiovascular events compared to those in the lowest quartile.
Observational (n=404)
No
Does a higher Atherogenic Index of Plasma (AIP) predict major adverse cardiovascular events in patients with chronic coronary syndrome?
An elevated Atherogenic Index of Plasma (AIP > 0.24) is an independent predictor of poor long-term cardiovascular outcomes in patients with chronic coronary syndrome.
Effect estimate: HR 7.892 (95% CI 1.818-34.269)
Absolute Event Rate: 31.7% vs 16.8%
p-value: p=0.006
BACKGROUND: The Atherogenic Index of Plasma (AIP) is a newly identified biomarker associated with lipid metabolism, demonstrating significant prognostic capabilities in individuals diagnosed with cardiovascular disease. However, its impact within the context of chronic coronary syndromes (CCS) remains unexplored. Thus, the present investigation sought to examine the potential association between AIP levels and long-term clinical outcomes in patients diagnosed with CCS. METHODS: A total of 404 patients diagnosed with CCS and who underwent coronary angiography were included in this study. The AIP index was calculated as log (triglycerides / high-density lipoprotein-cholesterol). The patients were categorized into four groups based on their AIP values: Q1 ( 0.328). The occurrence of major adverse cardiovascular events (MACE) was monitored during the follow-up period for all patients. Cox regression analysis and Kaplan-Meier curve analysis were employed to examine the relationship between AIP and MACE. Furthermore, ROC analysis was utilized to determine the optimal cut-off value of AIP for predicting clinical MACE. RESULTS: During the median 35 months of follow-up, a total of 88 patients experienced MACE. Notably, the group of patients with higher AIP values (Q4 group) exhibited a significantly higher incidence of MACE compared to those with lower AIP values (Q1, Q2, and Q3 groups) (31.7% vs. 16.8%, 15.7%, and 23.0% respectively; P = 0.023). The Kaplan-Meier curves illustrated those patients in the Q4 group had the highest risk of MACE relative to patients in the other groups (log-rank P = 0.014). Furthermore, the multivariate Cox regression analysis demonstrated that individuals in the Q4 group had a 7.892-fold increased risk of MACE compared to those in the Q1 group (adjusted HR, 7.892; 95% CI 1.818-34.269; P = 0.006). Additionally, the ROC curve analysis revealed an optimal AIP cut-off value of 0.24 for predicting clinical MACE in patients with CCS. CONCLUSION: Our data indicate, for the first time, that AIP is independently associated with poor long-term prognosis in patients suffering from CCS. The optimal AIP cut-off value for predicting clinical MACE among CCS patients was 0.24.
Alifu et al. (Thu,) conducted a observational in Chronic coronary syndrome (n=404). Atherogenic Index of Plasma (AIP) Quartile 4 (> 0.328) vs. AIP Quartile 1 (< -0.064) was evaluated on Major adverse cardiovascular events (MACE) (HR 7.892, 95% CI 1.818-34.269, p=0.006). Patients in the highest Atherogenic Index of Plasma quartile had a 7.892-fold increased risk of major adverse cardiovascular events compared to those in the lowest quartile.